全文获取类型
收费全文 | 628篇 |
免费 | 36篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 75篇 |
口腔科学 | 1篇 |
临床医学 | 27篇 |
内科学 | 246篇 |
皮肤病学 | 10篇 |
神经病学 | 3篇 |
特种医学 | 1篇 |
外科学 | 9篇 |
综合类 | 5篇 |
预防医学 | 5篇 |
药学 | 38篇 |
中国医学 | 2篇 |
肿瘤学 | 242篇 |
出版年
2023年 | 11篇 |
2022年 | 4篇 |
2021年 | 19篇 |
2020年 | 23篇 |
2019年 | 33篇 |
2018年 | 35篇 |
2017年 | 22篇 |
2016年 | 20篇 |
2015年 | 21篇 |
2014年 | 46篇 |
2013年 | 36篇 |
2012年 | 17篇 |
2011年 | 31篇 |
2010年 | 23篇 |
2009年 | 21篇 |
2008年 | 20篇 |
2007年 | 13篇 |
2006年 | 16篇 |
2005年 | 19篇 |
2004年 | 22篇 |
2003年 | 17篇 |
2002年 | 16篇 |
2001年 | 12篇 |
2000年 | 8篇 |
1999年 | 14篇 |
1998年 | 11篇 |
1997年 | 9篇 |
1996年 | 10篇 |
1995年 | 11篇 |
1994年 | 16篇 |
1993年 | 9篇 |
1992年 | 11篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 11篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 8篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 5篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有666条查询结果,搜索用时 15 毫秒
1.
Interleukin-10-1082A>G (rs1800896) Single Nucleotide Polymorphism is Not a Risk Factor of Chronic Lymphocytic Leukemia in Sudanese Population 下载免费PDF全文
Ameen Abdulaziz Basabaeen Enaam Abdelrhman AbdelgaderEbtihal Babekir AhmedNour Mahmoud AbdelateifSadia Osman AbdelrahimOmnia Mohamed SharifOsama Ali AltayebEman Abbass FadulIbrahim Osman Ibrahim 《Asian Pacific journal of cancer prevention》2022,23(9):3229-3235
Objective: The present study was conducted to examine the association between the IL-10-1082A>G (rs 1800896) polymorphism and risk of Chronic Lymphocytic Leukemia and to assess the correlation between this polymorphism and clinicopathological characters. Methods: A case-control study was conducted in Khartoum state, Sudan, during the period from April 2017 to April 2018, involved 110 CLL patients and 80 healthy volunteers as a control group. Physical examination, complete blood count, and immunophenotype were performed in all patients to confirm the diagnosis. Clinical staging such as Rai and Binet were studied. CD38 and ZAP70 were performed by flow cytometry. Blood samples were collected from all participants; DNA was extracted by using ANALYTIKJENA Blood DNA Extraction Kit and analyzed IL-10-1082A>G polymorphism by using Allele Specific-Polymerase Chain Reaction. The statistical analysis was performed using statistical package for social sciences version 23.0 software. Results: Frequency of AA, AG, and GG genotypes was 32.7%, 55.5%, and 11.8% for the patient group and 31.25%, 51.25%, and 17.5% in the control group, respectively. The genotype of IL-10 (-1082A>G) did not associate with susceptibility of CLL in our population. The study showed that the G allele of the IL-10 gene (-1082A>G) is associated with the male sex. However, no significant association was found between -1082A>G genotype and clinicopathological characters. Conclusion: Our results do not support the involvement of the IL-10 −1082A>G promoter gene polymorphism in the increased CLL susceptibility. IL-10-1082G allele (IL-10-1082AG or IL-10-1082GG) was found more frequently in males. Furthermore, no association was observed between the IL-10-1082A>G polymorphism and clinical stages systems as well as established poor prognostic markers. Finally, within the group of patients with CLL, there was no difference in the age at diagnosis and hematological parameters according to genotype distributions. 相似文献
2.
《Clinical Lymphoma, Myeloma & Leukemia》2019,19(10):678-685.e4
BackgroundMost important markers in chronic lymphocytic leukemia (CLL) are TP53 abnormalities, including mutations and deletions, and the mutational status of immunoglobulin heavy chain (IGHV) genes. However, some recent publications suggest that the IGHV mutational load could have a prognostic effect on CLL patients.Patients and MethodsWe performed a single-center retrospective study on 459 patients with productive rearrangement of the B-cell receptor to evaluate the prognostic and predictive role of IGHV mutational status and burden within the germline sequence. In particular we focused on FCR (fludarabine with cyclophosphamide, and rituximab)- (64 naive and 30 relapsed) and BR (bendamustine with rituximab)-treated patients (17 naive and 61 relapsed). A cutoff value of 2% of difference within the IGHV germline was used to define the IGHV mutational status.ResultsWe reported that unmutated IGHV (U-IGHV) patients were characterized by a significant shorter progression-free survival (PFS) and overall survival (P < .0001) compared with mutated IGHV (M-IGHV) patients. Moreover, treatment-naive M-IGHV patients experienced a long-term disease control after FCR or BR, with PFS reaching a plateau regardless of mutational load. In our series the extent of IGHV gene mutation did not provide further relevant prognostic data over the mutational status. Relapsed patients showed dismal outcome with chemoimmunotherapy regardless of IGHV status or load.ConclusionOur data, together with from those from the literature, confirmed the cutoff value of 2% to define the mutational status of IGHV gene and suggest that FCR/BR are good first-line treatment strategies for M-IGHV patients, whereas U-IGHV patients should be managed with B-cell receptor and/or B-cell lymphoma 2 (BCL2) inhibitors. 相似文献
3.
4.
The US Food and Drug Administration granted acalabrutinib approval as the second Bruton tyrosine kinase (BTK) inhibitor to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma as monotherapy or in combination with obinutuzumab. This approval was based on 2 phase 3 trials: ELEVATE-TN and ASCEND. There are several concerns with the design of these trials, including suboptimal treatment of patients in the control arm, expansion of the trial population, and lack of data regarding efficacy or tolerability compared with ibrutinib, a first-in-class drug. The Food and Drug Administration approval of acalabrutinib for patients with chronic lymphocytic leukemia and small lymphocytic lymphoma represents concerning drug approval patterns in the United States and a weakness in evidence generation. 相似文献
5.
6.
Evaluation of miRNA 223/125a and COBLL1 Expressions and ROR-1 Levels as Reliable Markers in B- chronic Lymphocytic Leukemia 下载免费PDF全文
Samia HusseinAbdallah S AbdelazemShimaa AbdelmoneemAL-Shabrawy M AbdelnabiTarek KhamisAhmed Ali ObayaHuda F Ebian 《Asian Pacific journal of cancer prevention》2022,23(8):2735-2742
Background: miRNA 223 /125a and Cordon-bleu Protein Like 1 (COBLL1) are novel biomarkers that can predict prognosis and guide treatment decisions in patients with chronic lymphocytic leukemia (CLL). Also, there is a growing interest in CLL monitoring based on flow cytometry of receptor tyrosine kinase-like orphan receptor-1 (ROR-1). Objective: This study aimed to evaluate the relationship between miRNA 223 /125a and COBLL1 expressions and ROR-1 expression in patients with CLL. Also, the study evaluated the relationship between the expression of these biomarkers with tumor staging and cancer progression. Methods: Our study included 40 patients newly diagnosed with B-CLL. In peripheral blood (PB), miRNA 223/125a and COBLL1 expressions were detected by real-time polymerase chain reaction (real-time PCR) and ROR-1 percentage was detected by flow cytometry before and after treatment. Results: High level of COBLL1 expression was statistically significantly associated with high ROR-1 percentage expression (P= 0.03). However, a high level of miRNA 223/125a expression was statistically significantly associated with low ROR-1 percentage expression (P=0.002). The sensitivity and specificity of ROR-1 as a predictor of high WBCs count after treatment were 96.6 and 81.1%, respectively. There was a statistically significant reduction of ROR-1 percentage after treatment compared to before treatment (P <0.001). Conclusion: ROR-1 percentage expression can be considered a possible prognostic predictor in CLL along with miRNA 223/125a and COBLL1 expressions. This can be explained by the significant correlation between ROR-1 and the studied molecular biomarkers; miRNA 223/125a and COBLL1. In addition, there was a significantly higher ROR-1 percentage in patients with higher WBC counts. Moreover, there was a significant reduction in ROR-1 percentage after treatment. 相似文献
7.
Omar Alkharabsheh Alhareth Alsayed Diana M. Morlote Amitkumar Mehta 《Current oncology (Toronto, Ont.)》2021,28(1):837
Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK inhibitors. Invasive fungal infections carry a high morbidity and mortality risk. There have been several case reports describing the association between aspergillosis and ibrutinib treatment, but none with acalabrutinib, to our knowledge. In this case report, we describe a patient with CLL who developed an intracranial Aspergillus fumigatus infection while receiving acalabrutinib. 相似文献
8.
9.
10.
Michele Dal Bo Tiziana D'Agaro Stefania Gobessi Antonella Zucchetto Sara Dereani Davide Rossi Francesco Zaja Gabriele Pozzato Francesco Di Raimondo Gianluca Gaidano Luca Laurenti Giovanni Del Poeta Dimitar G. Efremov Valter Gattei Riccardo Bomben 《Oncotarget》2015,6(22):19102-19117
The B-cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). By global microRNA profiling of CLL cells stimulated or not stimulated by anti-IgM, significant up-regulation of microRNAs from the miR-132~212 cluster was observed both in IGHV gene unmutated (UM) and mutated (M) CLL cells. Parallel gene expression profiling identified SIRT1, a deacetylase targeting several proteins including TP53, among the top-ranked miR-132 target genes down-regulated upon anti-IgM exposure. The direct regulation of SIRT1 expression by miR-132 was demonstrated using luciferase assays. The reduction of SIRT1 mRNA and protein (P = 0.001) upon anti-IgM stimulation was associated with an increase in TP53 acetylation (P = 0.007), and the parallel up-regulation of the TP53 target gene CDKN1A. Consistently, miR-132 transfections of CLL-like cells resulted in down-regulation of SIRT1 and an induction of a TP53-dependent apoptosis. Finally, in a series of 134 CLL samples, miR-132, when expressed above the median value, associated with prolonged time-to-first-treatment in patients with M CLL (HR = 0.41; P = 0.02). Collectively, the miR-132/SIRT1/TP53 axis was identified as a novel pathway triggered by BCR engagement that further increases the complexity of the interactions between tumor microenvironments and CLL cells. 相似文献